Cephalon, Valeant Pharmaceuticals deal

Cephalon's board recommended shareholders reject Valeant's bid to replace the board with seven new directors. The plan is part of Valeant's unsolicited offer to acquire Cephalon

Read the full 260 word article

How to gain access

Continue reading with a
two-week free trial.